Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Patients with troponin-negative acute coronary syndrome (ACS) are not routinely pre-treated
with P2Y12 inhibitors and the rate of high on-treatment platelet reactivity (HPR) remains
elevated after a loading dose of ticagrelor at the time of percutaneous coronary intervention
(PCI). This suggests that faster platelet inhibition with crushed ticagrelor , eptifibatide ,
or cangrelor is needed to reduce HPR and periprocedural myocardial infarction and injury
(PMI). The present study compared the effects of crushed ticagrelor vs. eptifibatide bolus +
clopidogrel in troponin-negative ACS patients undergoing PCI.